<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223742</url>
  </required_header>
  <id_info>
    <org_study_id>8-12-00 B</org_study_id>
    <nct_id>NCT01223742</nct_id>
  </id_info>
  <brief_title>Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy</brief_title>
  <official_title>ORAL ACETYL-L-CARNITINE THERAPY REDUCES FATIGUE IN HEPATIC ENCEPHALOPATHY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Catania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the effect of exogenous ALC on the both physical and
      mental fatigue in mild and moderate encephalopatic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>December 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>ACETYL-L-CARNITINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ACETYL-L-CARNITINE</intervention_name>
    <description>2 g acetylcarnitine taken orally twice a day.</description>
    <arm_group_label>ACETYL-L-CARNITINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo twice per day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Chronic hepatitis with spontaneous manifest HE (mental state grade 1 or 2 according
             to the West Haven criteria) and an NCT-A performance time &gt;30 seconds;

          -  2) Hyperammonemia (venous ammonia concentration &gt;50 mmol/L);

          -  3) Cooperative, hospitalised, adult patients with liver cirrhosis diagnosed by
             clinical, histological and ultrasonographic findings (reduced dimensions of the liver
             as well as splenomegaly) and oesophageal varices at stage II and III observed by
             endoscopy.

        Exclusion Criteria:

          -  1) Major complications of portal hypertension, such as gastrointestinal blood loss,
             hepatorenal syndrome or bacterial peritonitis;

          -  2) Acute superimposed liver injury;

          -  3) Patient with other neurological disease and metabolic disorders, diabetes mellitus,
             unbalanced heart failure and/or respiratory failure or end-stage renal disease;

          -  4) Alcoholic -toxic cirrhosis because toxic brain damage may interfere with the
             assessment of HE;

          -  5) Severe HE;

          -  6) Administration of anti-HE medications such as neomycin, branched-chain amino acids;

          -  7) Any additional precipitating factors such as high protein intake (additional
             high-protein meals), constipation or intake of psycho stimulants, sedatives,
             antidepressants, benzodiazepines, or benzodiazepines-antagonists (flumazenil),
             beta-adrenergic blockers, neuromuscular blocking agents, certain antibiotics;

          -  8) Patients with fever, sepsis or shock were also excluded to avoid variations caused
             by body temperature;

          -  9) Illiteracy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Cannizzaro Hospital</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

